drugset / Trial / NCT05250141
Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product
RandomizedCrossoverOpen-labelBasic science
Summary
This study will investigate the bioavailability in fasting male and/or non-pregnant and non- breast feeding female subjects of 1 tablet formulation containing Levodopa 250 mg and Carbidopa 25 mg. The study will be performed at a single site with 44 subjects. Participants will take 1 tablet of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 2 days between each study period.
Timeline
- Start
- 2022-02-14
- Primary completion
- 2022-02-17
- Completion
- 2022-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbidopa | Unknown | 25 mg | — |
| Subject | Levodopa | Small molecule | 250 mg | — |
Indications
No indication recorded.